BVNKF:OTCMKTS
Bavarian Nordic A/S
33,66 USD
arrow_upward
+0,01%(+0,0050) 1 zi
7 oct., 09:57:51 GMT-4 · USD
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru BVNKF...
Deschide
33,66 USD
Mare
33,66 USD
Mic
33,66 USD
Capitalizarea bursieră
2,61 mld.
Volum mediu
3,00
Volum
100,00
Prețul ridicat pe 52 de săptămâni
37,22 USD
Prețul redus pe 52 de săptămâni
27,69 USD
Beta
1,46
Acțiuni aflate în circulație
79,26 mil.
Nr. de angajați
2 K
Deschide
33,66 USD
Mare
33,66 USD
Mic
33,66 USD
Capitalizarea bursieră
2,61 mld.
Volum mediu
3,00
Volum
100,00
Prețul ridicat pe 52 de săptămâni
37,22 USD
Prețul redus pe 52 de săptămâni
27,69 USD
Beta
1,46
Acțiuni aflate în circulație
79,26 mil.
Nr. de angajați
2 K
Subiecte de știri
Din surse web și de la parteneri de știri
Investing News Network
·
acum 45 de minute
Snorkel AI Raises $350 Million to Help Push the Frontier: NYSE Content Update
Quartz
·
acum 1 oră
Dow drops 451 points as Treasury yields hit 24-year highs
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Despre Bavarian Nordic A/S
Director executivPaul Chaplin
Angajați1,91 K
Înființată la1 iul. 1992
Sediu-
Domeniu-